<DOC>
	<DOCNO>NCT02947048</DOCNO>
	<brief_summary>This five-arm designed ass safety L1-79 incorporate 15 prospectively randomize , placebo control patient 5 open label patient either 100 tid 200 tid dose 28 day . The open label patient assess purpose understanding PK/PD determine EKG change associate administration L1-79 . Additional safety information provide 30 patient randomize 2:1 active : placebo .</brief_summary>
	<brief_title>Safety L1-79 Young Adults With Autism</brief_title>
	<detailed_description>Protocol Number : HT 02-121 Protocol Title : Phase 2 Safety Study L1-79 Treatment Autism Study Phase : 2 The first cohort 20 patient enrolled receive L1-79 100 mg t.i.d. , comprise 3 group patient . The first group patient receive 100 mg differ others get blood sample draw PK analysis EKGs take . The safety PK data group submit FDA review acceptance 200 mg t.i.d . cohort enrol . The remain 15 patient cohort randomize receive either L1-79 100 mg t.i.d . placebo 2:1 basis ( 2 L1-79 patient placebo patient ) . While FDA review data first 5 patient 100 mg t.i.d . patient continue treat . The second cohort identical first . The initial 5 patient enrol differ others get blood sample draw PK analysis EKGs take . The remain 15 patient cohort randomize receive either L1-79 200 mg t.i.d . placebo 2:1 active : placebo . Sample Size : N=40 - Group 1 ( n=5 ) open100mg L1-79 ( 1x100mg capsule+1 placebo capsule ) - Group 2 ( n=10 ) blind100mg L1-79 ( 1x100mg capsule+1 placebo capsule ) - Group 3 ( n=5 ) open200 mg L1-79 ( 2x100 mg capsule ) - Group 4 ( n=10 ) blind200 mg L1-79 ( 2x100 mg capsule ) - Group 5 ( n=10 ) Placebo ( 2 placebo capsule ) All Groups receive assign study drug three-times daily Study Population : Male subject autism age 13 21 year age meet entry criterion able complete standardize measure allow participate study . Evaluation Schedule : Subjects evaluate within one week prior study accession , weekly throughout dose period , 4 week cessation treatment . The Assigned Dosage Groups ( Groups 1 3 ) PK blood draw EKG randomize group . Safety Measures : All Groups regularly schedule complete history physical examination include orthostatic blood pressure measurement , vital sign , CBC , differential , platelet count , urine analysis , serum analytes include : total protein , albumin , glucose , BUN , creatinine , direct total bilirubin , alkaline phosphatase , phosphorous , calcium , AST , ALT , sodium , potassium , chloride , bicarbonate , T4 , TSH , adverse event assessment . The Assigned Groups ( 1 3 ) also electrocardiograms take study screen visit weekly throughout treatment interval .</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<criteria>1 . Males sexually active 2 . 13 21 year age 3 . Signed informed consent 4 . Normal clinical laboratory value 5 . DSM5 compliant diagnosis autism spectrum disorder , confirm Autistic Diagnosis Interview Review ( ADIR ) , Autism Diagnosis Observation Schedule ( ADOS ) score consistent diagnosis autism 6 . No one concomitant medication treatment autism , stable least 2 week prior enrollment plan change psychosocial intervention trial 7 . No medication pathology 1 . Any comorbidities , include FragileX syndrome , epilepsy , Retts syndrome , ADHD , disease syndrome aside autism require treatment 2 . Any psychiatric disorder , range lab value 3 . DSM5 diagnosis schizophrenia , schizoaffective disorder , alcohol use disorder 4 . Active medical problem : unstable seizure ( &gt; 2 past month ) 5 . Concomitant physical illness</criteria>
	<gender>Male</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>